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Abstract The purpose of this investigation was the determi-
nation of the distribution of genotypes at single nucleotide
polymorphisms (SNPs) of the toll-like receptor 4 (TLR4)
and the toll-like receptor 9 (TLR9) in fetuses and newborns
congenitally infected with Toxoplasma gondii and the identi-
fication of genetic changes predisposing to infection develop-
ment. The study involved 20 fetuses and newborns with con-
genital toxoplasmosis and 50 uninfected controls. The levels
of IgG and IgM antibodies against T. gondii, as well as IgG
avidity, were estimated by enzyme-linked fluorescent assay
(ELFA) tests. T. gondii DNA loads in amniotic fluids were
assayed by the real-time (RT) quantitative polymerase chain
reaction (Q PCR) technique for parasitic B1 gene. TLR4 and
TLR9 SNPs were identified using a self-designed multiplex
nested PCR-restriction fragment length polymorphism
(RFLP) assay. Randomly selected genotypes at SNPs were
confirmed by sequencing. All the genotypes were tested for
Hardy–Weinberg equilibrium and TLR4 genotypes were ana-
lyzed for linkage disequilibrium. A correlation was studied
between the genotypes or haplotypes and the development
of congenital toxoplasmosis using a logistic regression model.
Single SNP analysis showed no statistically significant differ-
ences in the distribution of distinct genotypes at the analyzed
TLR4 and TLR9 SNPs between T. gondii-infected fetuses and
newborns and the controls. Taking into account the prevalence
of alleles residing within polymorphic sites, similar preva-
lence rates were observed in both of the studied groups. The
multiple SNP analysis indicated GTG variants at the TLR4
and TLR9 SNPs to be significantly less frequent in offspring
with congenital toxoplasmosis than in uninfected offspring
(p≤0.0001). TLR4 and TLR9 SNPs seem to be involved in
protection against congenital toxoplasmosis.
Introduction
Intrauterine infections are among the major causes of perinatal
morbidity and mortality. Nearly 40 % of pregnant Polish
women are infected with Toxoplasma gondii [1–3]. Particular-
ly dangerous are primary infections in pregnant women,
which are usually asymptomatic and, in approximately 30–
50 % of patients, result in transplacental transmission of
T. gondii to the fetus [4]. In fetuses and newborns with imma-
ture immune systems, consequential congenital infections
may bring about a very severe, if not fatal, course [4, 5].
Congenital toxoplasmosis occurs in approximately 0.07–
2.9 % of live births.
Toll-like receptor (TLR)/MyD88 signaling has been report-
ed as the key pathway in a non-specific antimicrobial response
against T. gondii [6, 7]. The glycosylphosphatidylinositol
(GPI) of T. gondiiwas demonstrated to trigger TLR4 signaling
pathways [8–10]. In inflammatory monocytes, T. gondii infec-
tion induced the production of interferon (IFN)-β through
TLR4 and MyD88 signaling [11]. A lack of tumor necrosis
factor (TNF) expression after T. gondii infection was charac-
teristic for mice deficient in TLR2 and TLR4, but not in TLR2
molecules alone [8]. Also, TLR9might have an important role
in the immunity against T. gondii, since TLR9-deficient mice,
infected with the parasite, were comparatively resistant to the
ileitis, revealing a decreased Th1 immune response [12, 13].
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Taking into account TLR genetic changes, possibly involved
in the development of T. gondii infections, the TLR9 1635
A>G single nucleotide polymorphism (SNP) was reported to
be associated with toxoplasmic retinochoroiditis among Bra-
zilian children with ocular toxoplasmosis [14]. So far, no pa-
per has ever reported the role of TLR4 and TLR9 SNPs in the
development of congenital infections with T. gondii. Howev-
er, previous studies commonly showed the role of TLR4 896
A>G and 1196 C>T SNPs in several pregnancy disorders,
including premature rupture of membranes (PROM),
bronchopulmonary dysplasia, and preterm labor [6, 15, 16].
In turn, the TLR9 1635 A>G SNP was also reported to be
involved in cervical cancer, mother-to-child transmission
(MTCT) of human immunodeficiency virus type 1 (HIV-1),
and an increased risk of low birth weight in infants, a risk of
maternal anemia, as well as a clinical picture of malaria in
pregnancy [17–19].
Considering the role of TLR molecules in the development
of T. gondii infection, as well as TLR genetic changes in preg-
nancy disorders, we decided to describe in this report the
prevalence rates of the genotypes and alleles at the TLR4
896 A>G, 1196 C>T, and TLR9 1635 G>A SNPs in fetuses
and newborns congenitally infected with T. gondii and com-
pare them to the prevalence rates observed in uninfected con-
trols. The haplotype prevalence rates were analyzed for TLR4
SNPs as well. Moreover, a multiple SNP analysis was per-
formed to identify the combined TLR SNP variants possibly
involved in the immune response against T. gondii. Addition-
ally, we also determined genotypes and alleles at the TLR2
2258 G>A SNP (rs5743708) among the studied groups of
patients. However, in the case of the TLR2 SNP, no contribu-
tion was found to congenital infection with T. gondii; hence,
no molecular data on this polymorphism were shown in the
current study.
Materials and methods
The study was performed with 20 fetuses and newborns with
congenital toxoplasmosis and 50 control fetuses and new-
borns without T. gondii intrauterine infection. Samples were
collected both retrospectively (15 infected cases and 23 con-
trols) and prospectively (five infected cases and 27 controls).
The specimens, selected for genetic studies of the infected
patients, included fetal amniotic fluid samples, obtained via
amniocentesis in pregnant women, all of them treated at the
Polish Mother’s Memorial Hospital Research Institute in
Lodz, between the years 2000 and 2014. The diagnosis of
intrauterine infections was based on maternal serological tests
and the clinical picture, including flu-like symptoms, fetal and
neonatal ultrasound markers related to the diseases, and the
presence of parasite or viral DNA in body fluids of the pa-
tients. Congenital infections with T. gondiiwere confirmed by
the presence of pathogenDNA in body fluids (amniotic and/or
ascitic fluids, umbilical cord blood) of the fetuses and new-
borns. The group of control cases included the offspring of
pregnant women seronegative for T. gondii. The study was
approved by the Research Ethics Committee at the Polish
Mother’s Memorial Hospital Research Institute. The samples,
previously collected for diagnostic purposes and anonymized,
were used for molecular analysis. Informed consent forms
were signed by the enrolled pregnant women prior to the
study.
Serological tests
Blood specimens were collected from the pregnant women
participating in the study by venipuncture on the first visit to
the Institute. Serum samples were obtained by centrifugation
and then stored at 4 °C before analysis. Serological tests were
performed at the Department of Clinical Microbiology of the
Institute.
Screening for T. gondii IgG antibodies was performed with
the enzyme-linked fluorescent assay (ELFA) VIDAS TOXO
IgG II (bioMérieux), while the levels of IgM antibodies were
estimated with the ELFA assay VIDAS TOXO IgM
(bioMérieux). T. gondii IgG avidity was determined using
the ELFA assay VIDAS TOXO IgG Avidity (bioMérieux).
The pregnant women were determined as possibly infected
with T. gondii in case of seroconversion during pregnancy
and/or serology, suggesting recent infection, based on IgM
seropositivity, as well as on low IgG avidity index. In order
to confirm recent infection, the suspected women, as well as
their fetuses and newborns, were tested for the presence of
parasite DNA, using real-time (RT) quantitative polymerase
chain reaction (Q PCR) assays for T. gondii B1 gene
fragments.
DNA isolation
Genomic DNAwas extracted from 5 ml of the amniotic fluid,
from 3 ml of the cerebrospinal fluid, or from 200 μl of the
umbilical cord blood of the fetuses, using a High Pure PCR
Template Preparation Kit (Roche, Mannheim, Germany), and
submitted to genetic studies of congenital toxoplasmosis. The
extracted DNA was diluted in 100 μl of elution buffer and
stored at −20 °C until molecular analyses.
Detection and quantification of T. gondii DNA
Parasite DNA was identified and quantified by a RT Q PCR
assay for a B1 gene fragment of 83 bps in length, as previously
described [20]. Forward and reverse primers and TaqMan
MGB p r o b e s e q u e n c e s w e r e a s f o l l ow s : 5 ′ -
CAAGCAGCGTATTGTCGAGTAGAT- 3 ′ , 5 ′ -
GCGTCTCTTTCATTCCCACATTTT-3′, and 5′-6-FAM-
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CAGAAAGGAACTGCATCCGTT-NFQ-3′, respectively
[20]. Standard curves, used in the quantitative analyses, were
plotted with serial 10-fold dilutions from 105 to 1 copy of
T. gondii RH strain (tebu-bio; 08-948-250). T. gondii DNA
copy numbers, present in PCR samples, were determined by
the absolute quantification analysis, done automatically by the
software, applied with the RT PCR instrument. RT Q PCR
assays were performed using a LightCycler® 2.0 Instrument
(Roche, Mannheim, Germany).
Determination of SNPs located in TLR4 and TLR9 genes
The TLR4 896 A>G and 1196 C>T SNPs and the TLR9 1635
G>A SNP were determined using the self-designed multiplex
nested PCR assay described in our recent paper [21]. The
sequences of external and internal primers, amplicon lengths,
and annealing temperatures used in the multiplex PCR are
shown in Table 1. External primer sequences were designed
using the Vector NTI Suite 5.5 software, whereas the internal
primers were taken from the literature [22–24]. Multiplex
nested PCR products were digested with NcoI, HinfI, or BstuI
endonucleases to determine the genotypes at the TLR4 896
A>G, TLR4 1196 C>T, or TLR9 1635 G>A SNPs, respective-
ly. TLR SNPs and genotypes were discriminated based on the
length of restriction fragments ([22–24]; see Table 1, Fig. 1).
Genotypes at the TLR4 896 A>G SNP were assessed for 69
out of the 70 studied fetuses and neonates, at the TLR4 1196
C>T SNP for 59 out of the 70 patients, while the genetic
variants at the TLR9 1635 G>A SNP were assessed for 64
out of the 70 analyzed offspring. Randomly selected PCR
products for the TLR4 and TLR9 SNP genotypes were then
sequenced by the Sanger method to confirm the outcomes of
the multiplex nested PCR-restriction fragment length poly-
morphism (RFLP) assay. In case of TLR4 SNPs, the sequenc-
ing was performed for three AA homozygotes and one AG
heterozygote at the TLR4 896 A>G SNP, as well as for two CC
homozygotes and one CT heterozygote at the TLR4 1196 C>T
SNP. Considering the TLR9 SNP, the sequencing was per-
formed for four GG homozygotes, ten GA heterozygotes,
and three AA homozygotes. The chromatograms, which illus-
trate the DNA sequences of PCR products for different TLR
SNPs, are shown in Fig. 2. Both the sequenced and the refer-
ence fragments of the analyzed TLR genes were compared,
using the BLASTN program for alignment of two (or more)
sequences (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_
TYPE=BlastSearch&BLAST_SPEC=blast2seq&LINK_
LOC=align2seq), and chromatograms were read using the
Sequence Scanner 1.0 and the Chromas Lite 2.1.1 programs.
Statistical analysis
The prevalence rates of genotypes and alleles at the TLR4 and
TLR9 SNPs that were identified in the examined fetuses and
newborns, both those infected with T. gondii and the controls,
were estimated by means of descriptive statistics. The study
groups were tested for the Hardy–Weinberg (H-W) equilibri-
um, linkage disequilibrium (LD), and haplotypes using the
SNPStats software (http://bioinfo.iconcologia.net/en/
SNPStats_web). The relationship between the genotypes or
alleles at the TLR SNPs and the development of T. gondii
infection was determined using cross-tabulation and Pearson’s
Chi-squared test, as well as the logistic regression model. The
estimation of haplotypes at the TLR4 SNPs, as well as the
multiple SNP analysis, was performed employing the
Table 1 Primers, annealing temperatures, and the lengths of products obtained in the multiplex nested polymerase chain reaction (PCR) assay for
single nucleotide polymorphisms (SNPs) in the toll-like receptor 4 (TLR4) and toll-like receptor 9 (TLR9) genes










External For: AAAACTTGTATTCAAGGTCTGGC 52 355 NcoI AA: 188
AG: 188, 168, 20
GG: 168, 20
Rev: TGTTGGAAGTGAAAGTAAGCCT





External For: AGTTGATCTACCAAGCCTTGAGT 52 510 HinfI CC: 407











External For: GTCAATGGCTCCCAGTTCC 52 292 BstUI GG: 135, 42
GA: 177, 135, 42
AA: 177
Rev: CATTGCCGCTGAAGTCCA
Internal For: AAGCTGGACCTCTACCACGA 59 177
Rev: TTGGCTGTGGATGTTGTT
a SNP single nucleotide polymorphism
b bps base pairs
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expectation–maximization (EM) algorithm. All the results
were determined to be statistically significant when they
reached the significance level of p≤0.050. The statistical anal-
ysis was, in part, supported by the NCSS 97 software.
Results
T. gondii DNA loads in fetal and neonatal body fluids
The median load of T. gondii DNA in the collected fetal am-
niotic fluid samples was 6.5×102 copies/ml and ranged from
3.0 to 9.7×103 copies/ml, while the mean parasitic load was
2.0×103 copies/ml. In case of cerebrospinal fluid samples, the
median T. gondii DNA load was 1.5×102 copies/ml, ranging
from 1.1×10 to 1.2×105 copies/ml, and the mean parasitic
load was 3.0×104 copies/ml. In neonatal umbilical cord blood
specimens, the parasitic load was 7.5×103 copies/ml.
Hardy–Weinberg equilibrium, linkage disequilibrium
The genotypes at the TLR4 896 A>G SNP preserved the H-W
equilibrium in T. gondii-infected fetuses and newborns (p=
1.000), while they were not in the H-W equilibrium among
the uninfected cases (p≤0.050). The genotypes at the TLR4
1196 C>T SNP did not preserve the H-Wequilibrium in either
of the analyzed groups (p≤0.050). In turn, the prevalence rates
of genotypes at the analyzed TLR9 1635G>A SNPwere in the
H-W equilibrium, both in the infected subjects as well as in
uninfected controls (p=1.000). The TLR4 896 A>G and 1196
C>T SNPs were seen in linkage disequilibrium among both
the infected and the control offspring (p≤0.050).
Prevalence rates of the genotypes at the TLR4 896 A>G,
1196 C>T, and TLR9 1635 G>A SNPs
Among the fetuses and newborns infected with T. gondii, the
prevalence rates of the AA and AG genotypes at the TLR4 896
A>G SNPwere 94.7 % (18/19) and 5.3 % (1/19), respectively
(see Table 2). In case of the TLR4 1196 C>T SNP, the CC and
CT genotypes were observed in 94.4 % (17/18) and 5.6 %
(1/18) of the patients, respectively. For the TLR9 1635 G>A
SNP, the GG, GA, and AA genotypes occurred in 20.0 %
(4/20), 55.0 % (11/20), and 25.0 % (5/20) of the fetuses and
newborns, respectively. Among the uninfected patients, the
prevalence rates of the AA, AG, and GG genotypes at the
TLR4 896 A>G SNP were 94.0 % (47/50), 2.0 % (1/50),
and 4.0 % (2/50), respectively. The CC, CT, and TT genotypes
at the TLR4 1196 C>T SNP were carried by 87.8 % (36/41),
7.3 % (3/41), and 4.9 % (2/41) of cases, respectively. Regard-
ing the TLR9 SNP, the prevalence rates of the GG, GA, and
AA genotypes were 18.2 % (8/44), 47.7 % (21/44), and
34.1 % (15/44), respectively. No relationship was observed
between single genotypes at the studied TLR SNPs and con-
genital toxoplasmosis development. Taking into account all
the analyzed SNPs, the multiple ACG variant at the TLR4
896 A>G, 1196 C>T, and TLR9 1635 G>A polymorphic sites
was most common among the fetuses and newborns with
congenital toxoplasmosis, with a prevalence rate of 52.8 %.
In the group of congenitally infected offspring, the ACA and
GTA variants were less frequently observed (44.5 % and
2.8 %, respectively). Considering the uninfected controls,
the most common multiple variant was ACA (56.6 %), while
the ACG, GTA, ATG, and GTG variants were less frequently
observed (34.9 %, 4.4 %, 2.4 %, and 1.7 %, respectively). The
GTG variants were significantly less frequent among the fe-
tuses and newborns with congenital toxoplasmosis as
Fig. 1 Agarose gel electrophoresis of polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) products for
profiling genotypes at the toll-like receptor 4 (TLR4) 896 A>G single-
nucleotide polymorphism (SNP) (a), the TLR4 1196 C>T SNP (b), and
the TLR9 1635 G>A SNP (c). DNA fragments which resulted from the
restriction analyses performed with NcoI (a), HinfI (b), and BstUI (c)
endonucleases were separated in 2 % agarose gels and stained with
ethidium bromide. The numbers on the right-hand side show the size of
resolved DNA fragments. M 50-bp DNA marker; Ud undigested PCR
product; AA, AG, GG, GA, CC, CT, TT genotypes at the studied TLR
polymorphisms
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compared to the uninfected offspring [0.0% vs. 1.7 %, respec-
tively; odds ratio (OR) 6.0×107; p≤0.0001].
The prevalence rates of the alleles located at the TLR4
and TLR9 SNPs
In the T. gondii-infected fetuses and newborns, the prevalence
rates of A and G alleles at the TLR4 896 A>G SNP were
97.4 % (37/38) and 2.6 % (1/38), respectively (see Table 3).
Considering the TLR4 1196 C>T SNP, the prevalence rates of
C and T alleles were 97.2 % (35/36) and 2.8 % (1/36), respec-
tively. At the region of the TLR9 SNP, the G allele was ob-
served with a prevalence rate of 47.5 % (19/40), while the A
allele was observed with a prevalence rate of 52.5 % (21/40).
Among the uninfected control fetuses and newborns, within
the TLR4 896 A>G polymorphic region, the A allele was
observed with a prevalence rate of 95.0 % (95/100), while
the G allele was observed with a prevalence rate of 5.0 %
(5/100). At the TLR4 1196 C>T SNP, the C allele occurred
with a prevalence rate of 91.5 % (75/82), while the T allele
occurred with a prevalence rate of 8.5 % (7/82). In case of the
TLR9 SNP, the G allele was observed with a prevalence rate of
58.0 % (51/88), while the G allele was observed with a prev-
alence rate of 42.0 % (37/88). In case of the TLR4 1196 C>T
SNP, the prevalence rate of the major allele was slightly in-
creased among the infected patients compared to the
Fig. 2 Chromatograms of DNA sequences containing the TLR4 896 A>GSNP (a, b), the TLR4 1196 C>T SNP (c, d), and the TLR9 1635G>ASNP (e–
g). DNA reverse strands were sequenced for all the analyzed SNPs. AA, AG, CC, CT, GG, GA genotypes at the described TLR SNPs
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uninfected controls. Taking into account all the analyzed al-
leles, the differences in their prevalence rates between the
studied patient groups were not significant.
Discussion
The multiple SNP analysis, performed in our study for both
the TLR4 and TLR9 SNPs, showed the GTG variants at the
TLR4 896 A>G, 1196 C>T, and TLR9 1635 G>A polymor-
phisms to be significantly less frequent among the fetuses and
newborns with congenital toxoplasmosis as compared to the
uninfected offspring. Previously, no study had ever shown any
simultaneous contribution of TLR4 and TLR9 SNPs to the
occurrence of T. gondii infection. However, a combined in-
volvement of other TLRs was reported in the development of
T. gondii infection inmice as well as in humans [25, 26]. Some
participation of both TLR2 and TLR4 in triggering an immune
response after T. gondii infection was observed in human
macrophages, while a sort of cooperation among TLR7
TLR9, and TLR11 was shown in mice [8, 25, 26]. The out-
comes of our study may suggest a contribution of all the an-
alyzed polymorphic sites in the immune response against
T. gondii. The studied TLR4 SNPs were in linkage disequilib-
rium; however, no difference was observed in the distribution
of TLR4 haplotypes between the T. gondii-infected fetuses and
Table 2 Single SNP analysis of the relationship between TLR polymorphisms and congenital Toxoplasma gondii infection
Gene polymorphism Genetic model Genotype Genotype prevalence rates; n (%)a ORb (95 % CI)c p-Valued
Infected cases Uninfected controls
TLR4 896 A>G Codominant AA 18 (94.7 %) 47 (94 %) 1.00 0.420
AG 1 (5.3 %) 1 (2 %) 2.61 (0.15–44.01)
GG 0 (0 %) 2 (4 %) 0.00 (0.00–NA)
Dominant AA 18 (94.7 %) 47 (94 %) 1.00 0.910
AG-GG 1 (5.3 %) 3 (6 %) 0.87 (0.08–8.92)
Recessive AA-AG 19 (100 %) 48 (96 %) 1.00 0.250
GG 0 (0 %) 2 (4 %) 0.00 (0.00–NA)
Overdominant AA-GG 18 (94.7 %) 49 (98 %) 1.00 0.490
AG 1 (5.3 %) 1 (2 %) 2.72 (0.16–45.85)
Log-additive – – – 0.66 (0.12–3.75) 0.620
TLR4 1196 C>T Codominant CC 17 (94.4 %) 36 (87.8 %) 1.00 0.450
CT 1 (5.6 %) 3 (7.3 %) 0.71 (0.07–7.3)
TT 0 (0 %) 2 (4.9 %) 0.00 (0.00–NA)
Dominant CC 17 (94.4 %) 36 (87.8 %) 1.00 0.410
CT-TT 1 (5.6 %) 5 (12.2 %) 0.42 (0.05–3.91)
Recessive CC-CT 18 (100 %) 39 (95.1 %) 1.00 0.220
TT 0 (0 %) 2 (4.9 %) 0.00 (0.00–NA)
Overdominant CC-TT 17 (94.4 %) 38 (92.7 %) 1.00 0.800
CT 1 (5.6 %) 3 (7.3 %) 0.75 (0.07–7.69)
Log-additive – – – 0.43 (0.07–2.78) 0.300
TLR9 1635 G>A Codominant AA 5 (25 %) 15 (34.1 %) 1.00 0.760
GA 11 (55 %) 21 (47.7 %) 1.57 (0.45–5.47)
GG 4 (20 %) 8 (18.2 %) 1.50 (0.31–7.21)
Dominant AA 5 (25 %) 15 (34.1 %) 1.00 0.460
GA-GG 15 (75 %) 29 (65.9 %) 1.55 (0.47–5.09)
Recessive AA-GA 16 (80 %) 36 (81.8 %) 1.00 0.860
GG 4 (20 %) 8 (18.2 %) 1.12 (0.3–4.28)
Overdominant AA-GG 9 (45 %) 23 (52.3 %) 1.00 0.590
GA 11 (55 %) 21 (47.7 %) 1.34 (0.46–3.87)
Log-additive – – – 1.25 (0.59–2.68) 0.560
p≤0.050 is considered significant
a n number of examined fetuses and newborns
bOR odds ratio
cCI confidence interval
d Logistic regression model
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newborns and the uninfected controls. Besides the lack of
papers on the role of genetic changes within TLR4 in the
development of toxoplasmosis, T. gondii infection was report-
ed to trigger TLR4 to activate proinflammatory transcription
factors and the expression of the pro-cytokines encoding
genes [6, 8, 10, 27]. Considering the polymorphic variability
of TLR4, some studies showed a certain functional association
of TLR4 SNPs with its activity [28–30]. The TLR4 896 A>G
and 1196 C>T SNPs were described to result in co-
segregating Asp299Gly and Thr399Ile missense mutations,
respectively, that are localized in the ectocellular domain of
the encoded protein [31, 32]. The mutations were reported to
diminish the TLR4 response to its ligand lipopolysaccharide
(LPS) in humans, while the Asp299Gly modification was in-
volved in the response interruption [31]. Additionally, the al-
teration caused a disruption of the TLR4 α-helical protein
structure and some extension of the β-strand [33]. The minor
allele at the 896 A>G SNP was reported to influence the
dimerization of TLR4, although its expression was not altered
[28]. Another study also showed both TLR4 896 A>G and
1196 C>T SNPs to impair the TLR4/MD dimerization re-
quired for activation of the downstream signaling [29]. In
our study, the prevalence of minor alleles at both TLR4 SNPs
was lower in congenitally infected fetuses and newborns, al-
though the difference was not significant. The significantly
lower frequency of GTG variants in the T. gondii-infected
offspring might suggest a protective role of the mutations in
the TLR4 gene against the development of parasitic infection.
Some previous studies showed a dual function of TLR4 in the
immune response after T. gondii infection [34–37]. In addition
to triggering TLR4 signaling, associated with activation of the
immune response, the parasite was also reported to use this
molecule to escape the immune responses [38–40]. Hence, the
modified TLR4 protein could be helpful for the host immune
system to interrupt T. gondii dissemination in the infected
organism. However, the number of fetuses and newborns con-
genitally infected with T. gondii and analyzed in the reported
study was rather small; hence, the current results should be
considered as preliminary and their further confirmation
would require the analysis of a larger group of infected fetuses
and newborns.
In the uninfected fetuses and newborns, the disruption of
the TLR9 signaling pathway, engaged in the induction of type
I IFNs, might also be driven by the altered TLR4 molecule.
TLR4 was reported to be able to enter endosomes and to
utilize TRAM and TRIF adapters to activate the IRF3 tran-
scription factor that contributes to the production of type I
IFNs [10, 41]. In turn, TLR9 was observed to cooperate with
IRF3 to induce inflammatory responses in liposome-DNA-
injected mice [42]. Similarly to TLR4, the TLR9 molecule
was suggested to be utilized by T. gondii in an immunosup-
pressive activity of the parasite that results in the inhibited
mobilization of intracellular TNF-α to the surface of murine
neutrophils [43]. Regarding TLR9 polymorphisms, it was re-
ported that the C allele at the TLR9 1635 G>A SNP correlated
with toxoplasmic retinochoroiditis in Brazilian children with
ocular toxoplasmosis [14]. Since the 1635 G>A SNP at the
TLR9 gene causes a synonymous amino acid change but no
alterations in the regulatory site, it was suggested that other
polymorphisms might affect the immune response against
T. gondii as well [14].
Considering the outcomes of our study, the protective
role of the analyzed TLR4 and TLR9 SNPs against con-
genital infection with T. gondii seems to be fairly plau-
sible. The GTG multiple variants at the TLR4 and TLR9
SNPs were significantly less frequent among the fetuses
and newborns with congenital toxoplasmosis than in the
uninfected controls. The contribution of the presented
multiple variants to the immune response against
T. gondii seems to be possible. However, we suggest
further studies with larger groups of patients to confirm
the role of TLR SNPs in congenital toxoplasmosis, as
well as to investigate the mechanisms which drive the
participation of TLR polymorphisms in the immune re-
sponse against the parasite.
Acknowledgments Sponsor: the Polish Ministry of Science & Higher
Education, Polish Mother’s Memorial Hospital—Research Institute—
Young Researcher Internal Grant No. 2012/63-MN.
Compliance with ethical standards “All procedures performed in
studies involving human participants were in accordance with the ethical
standards of the institutional and/or national research committee and with
the 1964 Helsinki declaration and its later amendments or comparable
ethical standards.”
Conflict of interest The authors declare that they have no conflict of
interest.
Table 3 Prevalence rates of the alleles at the TLR4 and TLR9
polymorphic sites






Alleles A 37 (97.4) 95 (95.0) 0.542
G 1 (2.6) 5 (5.0)
TLR4 1196 C>T
Alleles C 35 (97.2) 75 (91.5) 0.252
T 1 (2.8) 7 (8.5)
TLR9 1635 G>A
Alleles G 19 (47.5) 51 (58.0) 0.271
A 21 (52.5) 37 (42.0)
p≤0.050 is considered significant
aNo. number
b Pearson’s Chi-squared test
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